{"id":"NCT04362761","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy","officialTitle":"A Phase 3b Open-label Extension Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-04","primaryCompletion":"2022-12-21","completion":"2022-12-21","firstPosted":"2020-04-27","resultsPosted":"2023-07-28","lastUpdate":"2023-07-28"},"enrollment":172,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in participants with cystic fibrosis (CF) who are homozygous for F508del.","primaryOutcome":{"measure":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From Day 1 up to Week 52","effectByArm":[{"arm":"Part A: ELX/TEZ/IVA","deltaMin":160,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":29,"countries":["Australia","Belgium","Germany","United Kingdom"]},"refs":{"pmids":["37983082","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":172},"commonTop":["Headache","Nasopharyngitis","Infective pulmonary exacerbation of cystic fibrosis","Cough","Vaccination complication"]}}